Exercise Program Tested for Advanced Mesothelioma or Pancreatic Cancer Patients
Tests supervised exercise in adults with advanced mesothelioma or pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Exercise to Boost Immunity in Advanced Cancer
Key facts
- Where
- Sheffield, United KingdomSee the 2 sites
Where in United Kingdom
- Cancer Research Centre at Weston Park HospitalSheffield, United KingdomNo longer taking part
- Sheffield Hallam UniversitySheffield, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sheffield Teaching Hospitals NHS Foundation Trust
- Trial code
- NCT06310993
- Record updated
- 3 December 2024
- Original description
The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expressionRead full original descriptionShow less
Exercise to Boost Immunity in Advanced Cancer: Feasibility of Combined Aerobic Exercise and Resistance Training for Patients with Advanced Mesothelioma and Pancreatic Cancer
The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression
Inclusion: Patients about to start or who are undergoing first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma or patients about to start or who are undergoing first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer; Age over 18 years old; Histological or cytological diagnosis of mesothelioma or pancreatic cancer; ECOG Performance status 0-1 (to be assessed by clinician); Ability to provide informed consent.
Exclusion: Prior treatment with systemic anti-cancer treatment; Patients who have progressed on first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma; More than one primary cancer; Patients who have progressed on first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer; No histological or cytological diagnosis of mesothelioma or pancreatic cancer; Age below 18 years old; Uncontrolled brain or bone metastases; Patients with active co-morbidities that would prevent or limit their participation in the exercise intervention; ECOG Performance status of 2 or more; Unable to provide informed consent.